Interval Cytoreductive Surgery With or Without HIPEC for Ovarian Cancer (FOCUS / KOV-HIPEC-04)

Primary stage III-IV epithelial ovarian cancer randomizing between interval cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC)

Trial Details

NCT ID
NCT05827523
Phase
PHASE3
Sponsor
National Cancer Center, Korea
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • Cisplatin
Locations (sample)
  • Sejong, Chungcheongnam-do, South Korea
  • Sejong, Chungcheongnam-do, South Korea
  • Goyang-si, Gyeonggi-do, South Korea|37.65639,126.835
  • Goyang-si, Gyeonggi-do, South Korea|37.65639,126.835
  • Suwon, Gyeonggi-do, South Korea|37.27818,127.03164

Key Eligibility Criteria

  • Signed and written informed consent,
  • Patients ≥18, \<80 years old,
  • Diagnosed with histologically confirmed FIGO stage III-IV primary epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer tr…
  • Treated with interval complete cytoreduction, or cytoreduction with no more than 2.5 mm depth of residual disease,

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →